Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.79 |
| ▸ | PTGER2 | P43116 | 9/20 | 0.79 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.71 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609053 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5733516 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5733521 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5733514 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5733519 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL6166472 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL5812614 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL10029805 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL11562297 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 | |
| SCHEMBL6684191 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2PTGER3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | MERCK FROSST CANADA LTD. (CA) | 2005-10-27 | — | — | US | claimed |
| US-20050245429-A1 | Antioxidant compositions | PROCTER & GAMBLE COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | PTGER1, PTGER4, PTGER2 | PTGER4 2/4885PTGER2 3/4885PTGER3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.